drugset / Trial / NCT05689853
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
Timeline
- Start
- 2023-04-14
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK119 | Monoclonal antibody | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |